These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer]. Stepanov VN; Goriunov VG; Chechenin MG; Sivkov AV; Gubdurakhmanov II Urol Nefrol (Mosk); 1995; (6):33-6. PubMed ID: 8686122 [TBL] [Abstract][Full Text] [Related]
4. Use of cyproterone acetate in animal and clinical trials. Neumann F Gynecol Invest; 1971; 2(1):150-79. PubMed ID: 4949823 [No Abstract] [Full Text] [Related]
5. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer. Habenicht UF; Schröder H; el Etreby MF; Neumann F Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407 [No Abstract] [Full Text] [Related]
6. [Drug treatment of prostatic carcinoma]. Kool JC Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808 [No Abstract] [Full Text] [Related]
7. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Neumann F; Kalmus J Exp Clin Endocrinol; 1991; 98(2):71-80. PubMed ID: 1838080 [TBL] [Abstract][Full Text] [Related]
8. Cyproterone acetate--mechanism of action and clinical effectiveness in prostate cancer treatment. Schröder FH Cancer; 1993 Dec; 72(12 Suppl):3810-5. PubMed ID: 8252496 [No Abstract] [Full Text] [Related]
9. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735 [No Abstract] [Full Text] [Related]
10. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment. Luboshitzky R; Herer P; Shen-Orr Z Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776 [TBL] [Abstract][Full Text] [Related]
11. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study. Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607 [TBL] [Abstract][Full Text] [Related]
12. Treatment of female hyperandrogenism: estroprogestinic therapy at low dose in an inversal sequential scheme. Ragonesi FP; Lo Mastro F; Arena V; Ermini M Acta Eur Fertil; 1995; 26(4):141-3. PubMed ID: 9098476 [TBL] [Abstract][Full Text] [Related]
13. Pharmacology and potential use of cyproterone acetate. Neumann F Horm Metab Res; 1977 Jan; 9(1):1-13. PubMed ID: 66176 [No Abstract] [Full Text] [Related]
14. [Therapy of virginal prostatic cancer with cyproterone acetate]. Maier U Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180 [TBL] [Abstract][Full Text] [Related]